Clinical Research Directory

Inclusion Criteria: * Signed informed consent obtained. * Age ≥ 18 years, any gender. * Pathologically confirmed malignant tumors, including: * Glioblastoma * Head and neck squamous cell carcinoma * Non-small cell lung cancer * Esophageal cancer * Detectable PD-L1 expression in tumor tissue (based on immunohistochemistry or biopsy). * Measurable disease with at least one residual tumor lesion. * ECOG performance status of 0-1. * No contraindications to \[18F\]AlF-NOTA-PCP2 PET/CT imaging. * Willing and able to comply with study procedures and follow-up visits. Exclusion Criteria: * Participation in another interventional clinical trial. * Failure to recover from toxic effects or complications of prior interventions (≤ grade 1 or baseline levels, excluding fatigue or hair loss). * Pregnant or breastfeeding women. * Severe or uncontrolled systemic diseases, including: * Major, symptomatic arrhythmias or significant ECG abnormalities (e.g., complete left bundle branch block, second-degree or higher heart block, or ventricular arrhythmias). * Unstable angina or congestive heart failure (NYHA class ≥ 2). * Any arterial thrombotic or embolic events within 6 months before enrollment (e.g., myocardial infarction, cerebrovascular accident, transient ischemic attack). * Active or uncontrolled infections requiring systemic treatment. * Severe psychiatric disorders affecting study participation. * Any medical history, laboratory abnormality, or condition that may: * Interfere with study results. * Affect patient participation. * Pose an unacceptable risk as determined by the investigator. * Women of childbearing potential without a negative pregnancy test prior to study entry. * Known allergy or hypersensitivity to \[18F\]AlF-NOTA-PCP2 or any component of the radiopharmaceutical.